Budigalimab - AbbVie
Alternative Names: ABBV-181Latest Information Update: 28 Jun 2025
At a glance
- Originator AbbVie
- Developer AbbVie; Aceragen
- Class Antineoplastics; Antiretrovirals; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Programmed cell death 1 receptor antagonists; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II/III Liver cancer; Non-small cell lung cancer
- Phase II HIV-1 infections
- Phase I/II Pancreatic cancer
- Phase I Solid tumours
- No development reported Colorectal cancer; Endometrial cancer; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer; Small cell lung cancer; Squamous cell cancer
Most Recent Events
- 28 Jun 2025 No recent reports of development identified for phase-I development in HIV-1-infections(Treatment-experienced) in Australia (IV, Infusion)
- 28 Jun 2025 No recent reports of development identified for phase-I development in HIV-1-infections(Treatment-experienced) in Canada (IV, Infusion)
- 28 Jun 2025 No recent reports of development identified for phase-I development in HIV-1-infections(Treatment-experienced) in Puerto Rico (IV, Infusion)